# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-25-003421
**Filing Date:** 2025-9
**Character Count:** 2716
**Document Hash:** d550b6493e9cb14e5ddfe64c0a872f8e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-25-003421.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001178913-25-003421

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

------

![](image0.jpg)

Silexion Therapeutics Corp<br> 12 Abba Hillel Road

Ramat Gan, Israel 5250606

Telephone: +972-3-756-4999

September 30, 2025

#### VIA EDGAR
U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, DC 20549

Attention: Jason Drory

---

| | |
|:---|:---|
| Re: | **Silexion Therapeutics Corp** |
|  | **Registration Statement on Form S-3** |
|  | **Filed September 26, 2025**<br> **SEC File Number 333-290544** |

---

Dear Mr. Drory:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Silexion Therapeutics Corp hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated so that it will become effective at 5:00 p.m., Eastern Time on Tuesday, September 30, 2025, or as soon as practicable thereafter.

Please contact Gary Emmanuel, Esq., Greenberg Traurig, LLP, our U.S. legal counsel, at (212) 801-9337 or <u>Gary.Emmanuel@gtlaw.com</u>, or Jonathan M. Nathan, Adv., Meitar Law Offices, our outside (Israeli) legal counsel, at +972-52-312-5574 or <u>jonathann@meitar.com</u>, with any questions, and please notify either of them when this request for acceleration has been granted.

---

| | | |
|:---|:---|:---|
|  |  | Sincerely, |
|  |  | /s/ Ilan Hadar |
|  |  | Ilan Hadar |
|  |  | Chief Executive Officer |
| CC: | Mirit Horenshtein Hadar | Mirit Horenshtein Hadar |
|  | *Silexion Therapeutics Corp* | *Silexion Therapeutics Corp* |
|  | Gary Emmanuel, Esq.<br> *Greenberg Traurig, LLP*<br>Jonathan M. Nathan, Adv.<br> *Meitar Law Offices* | Gary Emmanuel, Esq.<br> *Greenberg Traurig, LLP*<br>Jonathan M. Nathan, Adv.<br> *Meitar Law Offices* |

---

------